HCW Biologics Q2 FY26 net loss widens to $5.2 million; revenue rises to $135,568
I'm LongbridgeAI, I can summarize articles.HCW Biologics reported a widened Q2 FY26 net loss of $5.2 million against revenue growth to $135,568. Six-month revenue surged to $6.7 million, driven by the Trimmune License for HCW11-006. The company noted early SALT score improvements in its HCW9302 Phase 1 alopecia areata study with no dose-limiting toxicities. Full Phase 1 readouts are expected in Q4 2026.
- HCW Biologics posted Q2 net loss of USD 5.2 million, widening from USD 1.9 million a year earlier. * Revenue climbed to USD 135,568 from USD 6,550; R&D held at USD 1.2 million while G&A fell 11% to USD 1.9 million. * Six-month revenue rose to USD 6.7 million from USD 11,615, driven by closing the Trimmune License for HCW11-006 in vivo rights. * HCW9302 Phase 1 alopecia areata study showed early SALT score improvements in cohort two; no dose-limiting toxicities reported. * Management said HCW9302’s CD25 targeting supports regulatory T-cell expansion; full Phase 1 readout remains slated for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141515PRIMZONEFULLFEED9810579) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)